A source of information and resource for small investors - "Patience is a Super Power" - "The Money is in the waiting"
Showing posts with label Foundries. Show all posts
Showing posts with label Foundries. Show all posts

Thursday, June 27, 2024

I asked ChatGPT, What a merger between Twist Biosciences and Ginkgo Bioworks might do for the growth of Synthetic Biology!

 


A merger between Twist Bioscience and Ginkgo Bioworks would create significant synergies due to their complementary strengths in synthetic biology and biotechnology. Here’s a detailed breakdown of the potential synergies each company would bring:

Twist Bioscience:

  1. DNA Synthesis Technology:

    • Strength: Twist Bioscience is a leader in DNA synthesis technology, known for its high-throughput DNA synthesis platform.
    • Synergy: Ginkgo Bioworks could leverage Twist's efficient and scalable DNA synthesis capabilities to enhance its organism engineering processes, reducing time and costs associated with DNA synthesis.
  2. Innovation in Synthetic Biology:

    • Strength: Twist has developed novel technologies for gene synthesis, gene assembly, and sequencing.
    • Synergy: Combining these innovations with Ginkgo's expertise in organism design could accelerate the development of new synthetic biology applications and products.
  3. Broad Market Applications:

    • Strength: Twist serves various markets, including healthcare, industrial chemicals, agriculture, and data storage.
    • Synergy: This market diversity could complement Ginkgo’s applications, opening new avenues for revenue growth and diversification.
  4. Robust Intellectual Property Portfolio:

    • Strength: Twist holds numerous patents in the field of DNA synthesis and synthetic biology.
    • Synergy: The merger would enhance the combined entity’s IP portfolio, strengthening its competitive position and protecting its technological innovations.

Ginkgo Bioworks:

  1. Organism Engineering Expertise:

    • Strength: Ginkgo Bioworks is renowned for its organism engineering capabilities, designing custom microbes for various applications.
    • Synergy: Twist’s DNA synthesis could significantly improve the efficiency and success rate of Ginkgo's organism engineering projects.
  2. Automated Foundries:

    • Strength: Ginkgo operates automated foundries that scale the process of designing and testing organisms.
    • Synergy: Integrating Twist’s DNA synthesis into these foundries could streamline workflows and accelerate development cycles, leading to faster time-to-market for new products.
  3. Extensive Partner Network:

    • Strength: Ginkgo has established partnerships with numerous companies across various industries.
    • Synergy: These partnerships could provide new business opportunities for Twist’s technologies and products, leveraging Ginkgo’s established network for market expansion.
  4. Data and Machine Learning Capabilities:

    • Strength: Ginkgo utilizes advanced data analytics and machine learning to optimize organism design and development.
    • Synergy: Combining Twist’s high-throughput DNA synthesis data with Ginkgo’s data analytics capabilities could enhance predictive modeling and improve the accuracy of synthetic biology projects.

Combined Synergies:

  1. Enhanced R&D Capabilities:

    • The merger would create a powerhouse in synthetic biology, combining Twist’s cutting-edge DNA synthesis with Ginkgo’s organism engineering, leading to unprecedented R&D capabilities and innovation potential.
  2. Cost Efficiency and Scalability:

    • The integration of Twist’s scalable DNA synthesis with Ginkgo’s automated foundries could lead to significant cost savings and improved scalability for synthetic biology projects.
  3. Expanded Market Reach:

    • The combined entity could leverage Twist’s diverse market presence and Ginkgo’s extensive partnerships to penetrate new markets and applications, driving revenue growth and market share.
  4. Accelerated Time-to-Market:

    • Synergies in technology and process integration would enable faster development cycles, allowing the combined company to bring new products and solutions to market more rapidly.
  5. Stronger Competitive Position:

    • The merger would create a more robust and competitive entity in the synthetic biology space, with a comprehensive technology portfolio and a strong IP position.

Overall, a merger between Twist Bioscience and Ginkgo Bioworks would likely result in a powerful synergy that enhances technological capabilities, operational efficiencies, market reach, and competitive strength in the rapidly evolving field of synthetic biology.

Wednesday, May 1, 2024

Ginkgo Bioworks is building out their BioManufacturing Foundry platform which mimics the building of semiconductor foundries of yester year!

 78.63% of #GinkgoBioworks ( $DNA) stock is owned by #Institutional #investors.

Here are some of the major institutional shareholders:

ARK Investment Management LLC owns a significant number of shares in Ginkgo Bioworks Holdings, Inc. (NYSE: DNA). As of the most recent filings, they held 182,192,185 shares during the 3rd quarter of 2023. 
Equitec Proprietary Markets LLC: Holds 672,488 shares (0.5% of the portfolio). Sumitomo Mitsui Trust Holdings Inc.: Holds 55,865,048 shares (2.595% of the portfolio).
(Note: M. Potter who served as President, Chief Executive Officer, and Chair of the board of Sumitomo Pharma America, and as the Chief Executive Officer of Sumitovant Biopharma, the parent company of five biotechnology companies, was added to the board of Ginkgo BioWorks on April 29th) Salem Investment Counselors Inc.: Holds 4,758,585 shares (0.221% of the portfolio). Vanguard Group Inc.: Holds 132,780,095 shares (6.169% of the portfolio). Lingotto Investment Management LLP: Holds 8,511,301 shares (0.402% of the portfolio). Additionally, during the previous two years, a total of 228 institutional investors and hedge funds held shares of Ginkgo Bioworks.
Some of the most heavily invested institutions include Baillie Gifford & Co., ARK Investment Management LLC, and Nikko Asset Management Americas Inc.. Institutional investors play a significant role in Ginkgo Bioworks’ ownership structure, with a mix of large investment firms and hedge funds holding substantial stakes in the company

Founded in 2008 by five #Scientists from #MIT, Ginkgo Bioworks is headquartered in #Boston. Their mission is to use #Biology to grow better products across diverse markets. They have developed a cell programming platform that enables the growth of biotechnology. Ginkgo’s platform allows for programming cells and designing organisms that behave in pre-defined ways. They work with various industries, from food to fragrance to pharmaceuticals. - - - - - - -
#Ginkgo collaborates with various organizations and companies like:
Pfizer
Pfizer has entered into a multi-target RNA discovery collaboration with Ginkgo Bioworks, cell engineering.
Ginkgo also collaborates with these partners:

#Motif #FoodWorks: Changing the future of #food. #Bayer: Designing #probiotics for plants. #Allonnia: Enabling bioremediation solutions. #Aldevron: Supporting the #Vaccine #SupplyChain. #Cronos Group: Unlocking potential in #Cannabinoids. #Synlogic: Engineering living #Medicines. #Moderna: Optimizing vaccine processes. #IARPA: Protecting valuable technology. #Robertet: Producing cultured ingredients. And more

  • Keep in mind the companies that collaborate with Ginkgo Bioworks to advance synthetic biology:

    1. OneOne Biosciences

      , a French biotech startup, is developing a comprehensive suite of agricultural microbial solutions. They have partnered with Ginkgo Bioworks to leverage their robust ag biologicals infrastructure, biotechnological expertise, and Strain Optimization Services. The collaboration aims to accelerate OneOne’s research and product development in agricultural microbial solutions, including a novel solution for production and delivery of ag microbials through the OneOne Multiplier™1.
    2. Synlogic: collaborates with Ginkgo Bioworks to develop a pipeline of novel “living” medicines based on engineered probiotics. They utilize Ginkgo’s cell programming platform to create innovative treatments.

    3. Biogen:

       and Ginkgo Bioworks have announced a gene therapy collaboration. Their goal is to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors3.

    4. Pfizer: Ginkgo Bioworks has a collaboration with Pfizer to advance the discovery and development of novel RNA molecules across priority research areas using Ginkgo’s proprietary RNA technology4.


    Ginkgo has also acquired competitors like Zymergen etc, and have a serious "first mover" advantage in the field as they continue to build a "moat" around their business that few if any, will be able to copykey points:
    1. Sustainability: Ginkgo’s platform enables leading pharmaceutical, food, and agriculture companies to develop more sustainable solutions. As the world increasingly looks to synthetic biology for emissions reduction and supply chain resilience, Ginkgo’s role becomes more critical.

    2. Biosecurity:

      Ginkgo’s biosecurity business unit, Concentric, is working on building infrastructure to monitor biological threats. They collaborate with organizations like the Centers for Disease Control and Prevention (CDC) to enhance pathogen monitoring and develop tools to prevent misuse of engineered biology.

    3. Employee Ownership and Care: Ginkgo is committed to thoughtful deployment of its platform. They’ve established a Caring Committee to assess potential impacts of their activities and integrate a Cost, Caring, and Risk Assessment (CCRA) process

    4. How to invest in Robots and Robotics going forward, through the back door method!